To compare the effects of injecting Intra- Articular Platelet-Rich Plasma and Hypertonic Dextrose Prolotherapy in Osteoarthritis Knee
- Conditions
- Health Condition 1: M15-M19- OsteoarthritisHealth Condition 2: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2021/06/034367
- Lead Sponsor
- King Georges Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 85
(1) Age =50 to <75 year old.
(2) Diagnosis of primary knee OA based on clinical criteria as defined by the American college of Rheumatology Association.
3) Moderate to severe knee pain for at least 3 months.
4) Failure to achieve pain and swelling reduction after 3 months of usual care, such as weight reduction, exercise, physical therapy and pharmacological treatment.
5) Radiographic evidence of knee OA (KL grade 1, grade 2, grade3).
6) BMI <30kg/m2
7) Patient willing to participate in the study.
1) History with uncontrolled Diabetes Mellitus.
2) OA knee: KL grade 4.
3) Patients on anticoagulant therapy.
4) Prior intra-articular knee injections within 3 months, other than platelet- rich plasma therapy (PRP therapy) and hypertonic dextrose prolotherapy
5) Inflammatory or post-infectious knee arthritis, such as clinically diagnosed rheumatoid arthritis, gouty arthritis, psoriatic arthritis and septic arthritis.
6) A history of previous knee pathology.
7) A history of any recent trauma to the hip joint or in the pelvic region interfering with ADL or causing any deformity
8) Patients with Hb < 10 gm/dl and platelet values <150,000/ml
9) Paralysis of lower extremities.
10) Significant effusion as defined by a ballotable patella.
11) Any disease other than osteoarthritis Knee
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the effects of Platelet-Rich Plasma and 25% Hypertonic Dextrose Prolotherapy in patients with Osteoarthritis Knee in terms of (1) Numeric Pain Rating Scale <br/ ><br>(2) Laquesne Knee Index (LKI)Timepoint: 6 weeks
- Secondary Outcome Measures
Name Time Method 1) Reduction of pain, according to Numeric pain rating scale (NPRS) <br/ ><br>2) Discomfort,walking and activities of daily living(ADL) according to Lequesne knee index (LKI) <br/ ><br>Timepoint: 0 week (immediately prior to first injection) <br/ ><br>6 weeks after the first injection.